OncoMatch/Clinical Trials/NCT06879041
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Is NCT06879041 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including AZD2287 and AZD2275 for metastatic castration-resistant prostate cancer.
Treatment: AZD2287 · AZD2275 · AZD2284 — The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Biomarker criteria
Allowed: BRCA1 mutation
A poly (adp-ribose) polymerase (PARP) inhibitor for participants with known BRCA mutation
Allowed: BRCA2 mutation
A poly (adp-ribose) polymerase (PARP) inhibitor for participants with known BRCA mutation
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: androgen receptor pathway inhibitor — mCRPC
At least 1 androgen receptor pathway inhibitor (ARPI)
Must have received: PARP inhibitor — mCRPC with BRCA mutation
A poly (adp-ribose) polymerase (PARP) inhibitor for participants with known BRCA mutation
Must have received: checkpoint inhibitor — mCRPC with MSI-H, dMMR, or TMB ≥ 10 mut/Mb
A checkpoint inhibitor for participants with known microsatellite instability-high (MSI-H), deficient mismatch pair (dMMR), or tumor mutational burden (TMB) ≥ 10 mut/Mb
Cannot have received: cytotoxic chemotherapy for CRPC
Exception: Taxanes for metastatic hormone sensitive prostate cancer (mHSPC) is acceptable if the last cycle Day 1 was > 12 months before first study treatment
No previous cytotoxic chemotherapy for CRPC. Taxanes for metastatic hormone sensitive prostate cancer (mHSPC) is acceptable if the last cycle Day 1 was > 12 months before first study treatment.
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Palo Alto, California
- Research Site · San Diego, California
- Research Site · Miami, Florida
- Research Site · Tampa, Florida
- Research Site · Chicago, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06879041 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cytotoxic chemotherapy for CRPC disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages